Harry Stylli, PhD, MBA

CEO and Chairman of the Board, Founder
Progenity

Harry Stylli

Harry Stylli Progenity

Harry Stylli is the Chairman and CEO of Progenity, and co-founded the company, guiding it from a small start-up with a single genetic testing platform to a key player in molecular diagnostics for women’s health. He is leading the company to develop precision medicine solutions through its genomic/epigenomic, proteomic, and microbiomic platforms, with both diagnostic and therapeutic applications.

Over the course of his career, he has worked to facilitate advancements in molecular diagnostic and therapeutic modalities that make a difference to society. Before co-founding Progenity in 2011, he transformed Sequenom from a distressed tools manufacturer into a molecular diagnostics company that was the first to develop and launch noninvasive prenatal testing (NIPT). This led to a worldwide transformation of prenatal testing for Down syndrome and other serious genetic conditions and later to the development of liquid biopsy technologies for cancer.

As a board member and Chief Restructuring Officer, he took Molecular Insight Pharmaceuticals through a business restructuring and chapter 11 bankruptcy, securing exit financing. As CEO of Xencor, he transformed the company from a computational protein design service provider into a biopharmaceutical company with a compelling antibody-based pipeline and pharma partnerships. He was the founding CEO of CovX Pharmaceuticals, a peptide/protein delivery platform based on modified antibodies that was acquired by Pfizer pre-IND.

Harry also co-founded Aurora Biosciences, which was purchased by Vertex Pharmaceuticals. The work of Aurora Biosciences, in collaboration with the Cystic Fibrosis Foundation, led to the discovery of Kalydeco by Vertex, the first targeted therapy for treating cystic fibrosis. He began his career at GSK research and development in the UK, moving into various roles of increasing responsibility.

In addition to his role at Progenity, Dr. Stylli is also a director of Immunis.AI and an advisor to Longitude Capital, a venture capital fund.

Harry holds a PhD from King’s College London GKT School of Medical Education, an MBA from The Open University (UK), and a BSc (hons) from University of East London. He also supports several charitable organizations, serving as a board member for the Duke Institute for Brain Sciences and as honorary director for the ABC Youth Foundation.

Support